Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

605 results
Display

Refractory Hepatic Hydrothorax in Chronic Hepatitis C Controlled by Direct-acting Antivirals

Kim MH, Kim DK, Eun HS, Rou WS, Kim SH, Lee BS

Hepatic hydrothorax is a transudative pleural effusion that complicates advanced liver cirrhosis. Patients refractory to medical treatment plus salt restriction and diuretics are considered to have refractory hepatic hydrothorax and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
An integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infection

Lee YJ, Heo J, Kim DY, Chung WJ, Tak WY, Kim YJ, Paik SW, Sim E, Kulasingam S, Talwani R, Haber B, Hwang P

BACKGROUND/AIMS: In the Republic of Korea, an estimated 231,000 individuals have chronic hepatitis C virus (HCV) infection. The aim of the present analysis was to evaluate the safety and efficacy...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Upcoming direct acting antivirals for hepatitis C patients with a prior treatment failure

Parigi TL, Torres MC, Aghemo A

Despite the high efficacy of direct acting antivirals (DAAs) not all patients successfully clear hepatitis C virus infection, in fact, approximately 1–3% fail to reach a sustained virological response 12...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Management Outcome and Expansion Strategy for Treatment of Hepatitis C Virus Infection among Persons Affected with Leprosy

Lee MW, Park HC

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Multimodality Imaging Features of Cardiac Fungal Infection: A Case Report

Talib N, Mohammed Y, Abas SI, Ramli KA

We present a 38-year-old man with hepatitis C and history of intravenous drug use who presented with fever and hemoptysis. Initial chest CT showed bronchiectasis with an intracavitary lesion consistent...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
What is the Long-term Benefit of Direct-acting Antiviral Therapy in Chronic Hepatitis C?

Kim JW

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Durability of Sustained Virologic Response and Improvement of Fibrosis Markers after Daclatasvir and Asunaprevir Treatment in Genotype 1b Hepatitis C Virus-Infected Patients: a Real Life and Multicenter Study

Shin SK, Lee JW, Ra H, Kwon OS, Shin JB, Jin YJ, Lee S, Han KJ, Kim YN, Kim TH, Kim YS, Kim JH

BACKGROUND: The long-term data with direct acting antiviral agents were rare. This study investigated the durability of a sustained virologic response (SVR) and the improvement of fibrosis after daclatasvir and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Are there differences in risk factors, microbial aspects, and prognosis of cellulitis between compensated and decompensated hepatitis C virus-related cirrhosis?

Hassan EA, Rehim AS, Abdel-Malek MO, Ahmed AO, Abbas NM

BACKGROUND/AIMS: Cellulitis is a common infection in patients with liver cirrhosis. We aimed to compare risk factors, microbial aspects, and outcomes of cellulitis in compensated and decompensated hepatitis C virus...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Underlying liver disease and advanced stage liver cancer are associated with elevated neutrophil-lymphocyte ratio

Wong L, Bozhilov K, Hernandez , Kwee S, Chan O, Ellis L, LeMarchand L

BACKGROUND/AIMS: Inflammation-based scores, such as the neutrophil-to-lymphocyte ratio (NLR), have been associated with prognosis in hepatocellular carcinoma (HCC); but variable cut-off values and potential lack of specificity have limited the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Development and surveillance of hepatocellular carcinoma in patients with sustained virologic response after antiviral therapy for chronic hepatitis C

Na SK, Song BC

Hepatitis C virus (HCV) infection is a major risk factor for liver cirrhosis and hepatocellular carcinoma (HCC), and is a leading cause of liver-related deaths worldwide. Recently available direct-acting antiviral...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Comparison of the Clinical Characteristics and Outcomes between Leprosy-Affected Persons in Sorokdo and the General Population Affected by Chronic Hepatitis C in Korea

Ahn YH, Park H, Lee MJ, Kim DH, Cho SB, Cho E, Jun CH, Choi SK

BACKGROUND/AIMS: Patients with Hansen’s disease are the most vulnerable to hepatitis C. However, no data on the treatment efficacy of direct-acting antiviral agents (DAAs) are available in this group. Therefore,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Platelet count is associated with sustained virological response rates in treatments for chronic hepatitis C

Jun BG, Park EJ, Lee WC, Jang JY, Jeong SW, Kim YD, Cheon GJ, Cho YS, Lee SH, Kim HS, Lee YN, Kim SG, Kim YS, Kim BS

BACKGROUND/AIMS: This study was conducted to clarify the sustained virological response (SVR) prediction ability of baseline and treatment-related factors in patients with chronic hepatitis C virus (HCV) infection. METHODS: This retrospective...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Prediction and Staging of Hepatic Fibrosis in Children with Hepatitis C Virus: A Machine Learning Approach

Barakat NH, Barakat SH, Ahmed N

OBJECTIVES: The aim of this study is to develop an intelligent diagnostic system utilizing machine learning for data cleansing, then build an intelligent model and obtain new cutoff values for...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world

Oh JY, Kim BS, Lee CH, Song JE, Lee HJ, Park JG, Hwang JS, Chung WJ, Jang BK, Kweon YO, Tak WY, Park SY, Jang SY, Suh JI, Kwak SG

BACKGROUND/AIMS: Previous studies have reported a high rate of sustained virologic response (SVR) and a low rate of serious adverse events with the use of daclatasvir (DCV) and asunaprevir (ASV)...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Evaluation of Noninvasive Liver Fibrosis Blood Markers in Patients with Chronic Hepatitis B and Hepatitis C

Lee JH, Cho J, Kim J, Uh Y, Youn KJ

BACKGROUND: Liver fibrosis evaluation is an important issue in chronic liver disease patients. We aimed to develop noninvasive liver fibrosis biomarkers based on transient elastography (TE, FibroScan®) through retrospective review...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Direct-acting antivirals response in hepatocellular carcinoma: Does the presence of hepatocellular carcinoma matter?

Huang CF, Yu ML

During the clinical trial development of directly acting antivirals (DAAs), evidence regarding the treatment efficacy in chronic hepatitis C patients with hepatocellular carcinoma (HCC) was scarce because these patients have...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection

Sato S, Moriya K, Furukawa M, Saikawa S, Namisaki T, Kitade M, Kawaratani H, Kaji K, Takaya H, Shimozato , Sawada Y, Seki K, Kitagawa K, Akahane T, Mitoro A, Okura Y, Yamao J, Yoshiji H

BACKGROUND/AIMS: L-carnitine not only alleviates hyperammonemia and reduces muscle cramps in patients with liver cirrhosis, but also improves anemia in patients with chronic hepatitis and renal dysfunction. This study prospectively...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients

Mölleken , Ahrens M, Schlosser , Dietz J, Eisenacher M, Meyer HE, Schmiegel , Holmskov U, Sarrazin C, Sorensen G, Sitek B, Bracht T

BACKGROUND/AIMS: An estimated 80 million people worldwide are infected with viremic hepatitis C virus (HCV). Even after eradication of HCV with direct acting antivirals (DAAs), hepatic fibrosis remains a risk...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Biomarker microfibril-associated glycoprotein 4 for non-invasive diagnosis and therapeutic evaluation of hepatic fibrosis in patients with hepatitis C

Eom YW, Baik SK

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Discussion on critical points for a tailored therapy to cure hepatitis C virus infection

Marascio N, Quirino A, Barreca GS, Galati L, Costa C, Pisani V, Mazzitelli M, Matera G, Liberto MC, Focà A, Torti C

Hepatitis C virus (HCV) infects around 71 million people worldwide and in 2018 it is still a major health problem. Since 2011, anti-HCV therapy with availability of direct-acting antiviral drugs...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2023 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr